Clinical trials: ESRD
Renal Insufficiency, Kidney Diseases
A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis
This study is conducted to evaluate the pharmacokinetics and safety of INCB161734 in participants with impaired renal function and participants on hemodialysis.
- Trial name
- NCT07854249
- Testing
- INCB161734
- Volunteers
- 24 people
- Sponsor
- Incyte Corporation
Renal Insufficiency, Chronic
Catheter System Feasibility Clinical Trial
Feasibility clinical study to evaluate the safety and effectiveness of the catheter system for the percutaneous creation of an arteriovenous fistula for patients with end stage renal disease requiring dialysis access.
- Trial name
- NCT02816398
- Testing
- Percutaneous creation of an arteriovenous fistula
- Volunteers
- 26 people
- Sponsor
- Medtronic Endovascular
Interstitial Lung Disease, Chronic Kidney Diseases
Safety, Tolerability, PK and PD Study of AD-214 Administered to Healthy Volunteers and Patients With Interstitial Lung Disease or Chronic Kidney Disease
This is a Phase I, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of a 10 mg/kg dose of AD-214 when administered to healthy volunteers…
- Trial name
- NCT05914909
- Testing
- AD-214
- Where
- Australia
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AdAlta Limited
Diabetes, Diabetes Mellitus, Type 1
Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney Disease
This study is conducted in Asia. The aim of this observational study is to investigate the clinical safety profile and effectiveness while using SC NovoRapid™ (insulin aspart) in patients with coexisting diabetes and kidney…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Chronic Kidney Disease
- Trial name
- NCT00849316
- Testing
- insulin aspart
- Sponsor
- Novo Nordisk A/S
Anemia Associated With Chronic Kidney Disease
Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD
This open-labeled, multicenter study is designed to evaluate the efficacy, safety and PK/PD of roxadustat in ESA-naïve and ESA-treated pediatric patients with CKD Stages 3, 4, and 5, as well as end-stage renal disease (ESRD) who…
- Trial name
- NCT04621331
- Testing
- Roxadustat
- Where
- 4 sites in United States
- Sponsor
- Kyntra Bio
Anemia, Chronic Kidney Disease
A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12)
This study will evaluate the efficacy and safety of intravenous MK2578, given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving erythropoietin stimulating…
- Trial name
- NCT00924781
- Testing
- MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline, MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline, MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline
- Volunteers
- 39 people
- Sponsor
- Merck Sharp & Dohme LLC
Kidney Transplantation in Highly Sensitized Patients
Imlifidase Prior to Kidney Transplant in Highly Sensitised Children
The goal of this clinical trial is to learn about the efficacy and safety of imlifidase in highly sensitized paediatric patients, 1-17 years old, with end stage renal disease (ESRD).
- Trial name
- DINKY (NCT05753930)
- Testing
- Imlifidase
- Where
- 6 sites in Finland, France and 3 more
- Volunteers
- 10 people
- Sponsor
- Hansa Biopharma AB
Hemodialysis Access
Safety of Vascugel Treatment After Creation of Arteriovenous Access for Hemodialysis Use
Vascugel™ is safe when placed at the anastomotic site at the time of surgery during creation of an AV graft or fistula for hemodialysis access.
- Trial name
- NCT00479180
- Testing
- Vascugel
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Pervasis Therapeutics, Inc
End-Stage Renal Disease Requiring Haemodialysis
DisTal Arterio-Venous Fistula Feasibility
The goal of this clinical trial is to evaluate, in a clinical setting, the feasibility of vein enlargement at the site of the arteriovenous fistula created percutaneously, using the DisTal device ("DisTal AVF").
- Trial name
- DisTal (NCT07786025)
- Testing
- DisTal
- Where
- Dominican Republic
- Volunteers
- 100 people
- Sponsor
- Distal Inc.
Renal Impairment
Safinamide Renal Impairment Trial
The primary purpose of the trial is to investigate the pharmacokinetics (behaviour of the compound in the body) of safinamide in subjects with different degrees of renal impairment in comparison to matched subjects with normal…
- Trial name
- NCT01374113
- Testing
- 50mg safinamide
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Newron Pharmaceuticals SPA
Renal Failure, End Stage Renal Disease
Comparative Safety and Clinical Performance of Dialyzers Applied During Post-dilution Online Hemodiafiltration
The clinical Investigation will be performed to compare the safety and clinical performance profile of different hemodialyzers, all applied in on-line postdilution hemodiafiltration
- Trial name
- eMPORA II (NCT03611218)
- Testing
- Dialyzer
- Where
- 6 sites in Germany
- Volunteers
- 71 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Anemia in Chronic Kidney Disease
An Exploratory Study to Evaluate FMX-8 to Treat Anemia in CKD
FMX-8 is a new type of drug being tested for the treatment of anemia in chronic illnesses.
- Trial name
- NCT02228655
- Testing
- FMX-8
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- FerruMax Pharmaceuticals, Inc.
Chronic Kidney Disease
A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney Disease
The purpose of the study was to evaluate the efficacy and safety of HS-10390 in participants with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) ≥ 30 and <90 mL/min/1.73 m^2, and urinary albumin to…
- Trial name
- NCT07555054
- Testing
- HS-10390, Irbesartan
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Renal Impairment, Multiple Myeloma
PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function
This was a multicenter study of the pharmacokinetics (PK) of melphalan during treatment with melflufen and dexamethasone in patients with relapsed refractory multiple myeloma (RRMM) and impaired renal function.
- Trial name
- BRIDGE (NCT03639610)
- Testing
- Melflufen, Dexamethasone
- Where
- 10 sites in Czechia, Greece and 1 more
- Volunteers
- 35 people
- Sponsor
- Oncopeptides AB
Renal Impairment
Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)
The purpose of this study is to compare the plasma and urine pharmacokinetics (PK) of MK-3402 in participants with impaired renal function and healthy control participants, to investigate the extent to which MK-3402 is removed…
- Trial name
- NCT04678505
- Testing
- MK-3402
- Where
- 2 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Participants With Moderate and Severe Renal Impairment and Healthy Participants
A Study to Investigate the Pharmacokinetics and Safety of PKN605 in Participants With Moderate and Severe Renal Impairment Compared to Matched Control Subjects With Normal Renal Function
The purpose of this trial is to assess any potential exposure increases of PKN605 in participants with reduced renal function to support decisions on participant eligibility and dosing in subsequent clinical trials of PKN605.
- Trial name
- NCT07797322
- Testing
- PKN605
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Kidney Impairment
Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Severe Kidney Disease
This study will assess the effect of severe kidney impairment on the pharmacokinetics (PK), safety and tolerability of Leritrelvir.
- Trial name
- NCT06160622
- Testing
- Leritrelvir
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Renal Failure, End Stage Renal Disease
Comparative Clinical Performance of Dialyzers Applied During High Volume Online Haemodiafiltration
The clinical investigation will be performed to generate clinical data on clearances and removal rates for ß2-microglobulin and other uremic toxins and on clinical adverse events of the modified polysulfone membrane to fulfil…
- Trial name
- comPERFORMStud (NCT04102280)
- Testing
- Dialyser
- Where
- 4 sites in Germany
- Volunteers
- 52 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Hyperlipidemia, Mixed Dyslipidemia
Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab
The primary objective of this study was to evaluate the pharmacokinetics of evolocumab after a single 140 mg subcutaneous (SC) dose in aduts with normal renal function or severe renal impairment or end-stage renal disease (ESRD)…
- Trial name
- NCT02275156
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Amgen
Chronic Kidney Disease and Hypertension
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in…
- Trial name
- BaxDuo-Pacific (NCT06742723)
- Testing
- Baxdrostat/dapagliflozin
- Where
- 771 sites in United States, Argentina and 40 more
- Volunteers
- 5,000 people
- Sponsor
- AstraZeneca